{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:46:54Z","timestamp":1782982014483,"version":"3.54.5"},"reference-count":77,"publisher":"The Korean Academy of Tuberculosis and Respiratory Diseases","issue":"3","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["e-trd.org"],"crossmark-restriction":true},"short-container-title":["Tuberc Respir Dis"],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:p>Biologic and targeted small-molecule therapies have revolutionized the management of severe asthma by specifically targeting key inflammatory pathways. These advances have led to significant reductions in exacerbations, improved lung function, and decreased dependence on corticosteroids. However, a substantial number of patients still experience breakthrough exacerbations and inadequate disease control, indicating that there are residual inflammatory mechanisms beyond the classical type-2 pathways. Current biologics that target immunoglobulin E, interleukin-5, interleukin-4 receptor alpha, and thymic stromal lymphopoietin show efficacy in biomarker-defined populations. Yet, their clinical benefits are closely tied to baseline type-2 biomarkers, and they often fall short for patients with non-type-2 or mixed inflammatory phenotypes. Emerging evidence from transcriptomic and clinical studies suggests that factors such as epithelial dysfunction, innate immune activation, and tissue repair pathways contribute to ongoing disease instability, even with targeted cytokine blockade. These insights have spurred the development of new therapeutic strategies, including biologics aimed at upstream epithelial alarmins like interleukin-33, oral small-molecule inhibitors such as Bruton tyrosine kinase inhibitors, lineage-directed eosinophil-suppressing agents, inhaled biologics, and nanobody-based therapies. Additionally, long-acting and ultra- long-acting biologics are designed to enhance treatment durability and adherence, while bispecific antibodies integrate both upstream and downstream inflammatory inhibition into a single molecular construct. These advancements signify a shift towards broader and more sustained modulation of inflammatory pathways. Future progress in asthma treatment will hinge on integrating insights from epithelial biology, refining biomarker- guided patient selection, and developing multispecific and upstream-targeting therapies to address persistent disease heterogeneity and improve long-term clinical outcomes.<\/jats:p>","DOI":"10.4046\/trd.2026.0033","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:30:26Z","timestamp":1776814226000},"page":"347-358","update-policy":"https:\/\/doi.org\/10.4046\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging Targeted Therapies in Asthma: From Upstream Epithelial Biology to Novel Biologic and Small-Molecule Strategies"],"prefix":"10.4046","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4379-0260","authenticated-orcid":true,"given":"Hyun Woo","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Respiratory and Critical Care, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2481","reference":[{"key":"ref1","first-page":"783","type":"journal-article","volume-title":"Asthma","author":"Papi","year":"2018"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2024-222679","type":"journal-article"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2025.102381","type":"journal-article"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0088-2024","type":"journal-article"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0628","type":"journal-article"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ph18071021","type":"journal-article"},{"key":"ref7","first-page":"1","type":"journal-article","volume-title":"Next-generation therapeutic approaches for uncontrolled asthma: insights into the heterogeneity of non-type 2 inflammation","author":"Kim","year":"2024"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14041079","type":"journal-article"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1208606","type":"journal-article"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2021.01.027","type":"journal-article"},{"key":"ref11","first-page":"2004233","type":"journal-article","volume-title":"Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies","author":"Rogliani","year":"2021"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(20)30389-1","type":"journal-article"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/aci.0000000000000284","type":"journal-article"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)01625-3","type":"journal-article"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1403290","type":"journal-article"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)60988-x","type":"journal-article"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1703501","type":"journal-article"},{"key":"ref18","first-page":"2486","type":"journal-article","volume-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","author":"Castro","year":"2018"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2014.03.010","type":"journal-article"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2034975","type":"journal-article"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2174\/0929867327666200713184659","type":"journal-article"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2678","type":"journal-article"},{"key":"ref23","first-page":"2115","type":"journal-article","volume-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting b2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","author":"Bleecker","year":"2016"},{"key":"ref24","first-page":"243","type":"journal-article","volume-title":"Endotypes of allergic diseases and asthma: an important step in building blocks for the future of precision medicine","author":"Agache","year":"2016"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2147\/jaa.s153097","type":"journal-article"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201809-1817pp","type":"journal-article"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0238-2023","type":"journal-article"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114012","type":"journal-article"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200807-1126oc","type":"journal-article"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2025.08.027","type":"journal-article"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.23822\/eurannaci.1764-1489.271","type":"journal-article"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00826-2023","type":"journal-article"},{"key":"ref33","first-page":"237","type":"journal-article","volume-title":"Peripheral blood transcriptomic clusters uncovered immune phenotypes of asthma","author":"Lee","year":"2022"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.01.031","type":"journal-article"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0347-8","type":"journal-article"},{"key":"ref36","first-page":"122","type":"journal-article","volume-title":"Induction of epithelial-mesenchymal transition in primary airway epithelial cells from patients with asthma by transforming growth factor-beta1","author":"Hackett","year":"2009"},{"key":"ref37","first-page":"154","type":"journal-article","volume-title":"Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family","author":"Cayrol","year":"2018"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2010.10.006","type":"journal-article"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2024257","type":"journal-article"},{"key":"ref40","first-page":"59","type":"journal-article","volume-title":"An official American Thoracic Society\/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice","author":"Reddel","year":"2009"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00183-2025","type":"journal-article"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.03.044","type":"journal-article"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1533335","type":"journal-article"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.70174","type":"journal-article"},{"key":"ref45","first-page":"1235","type":"journal-article","volume-title":"Involvement of Bruton's tyrosine kinase in FcepsilonRI-dependent mast cell degranulation and cytokine production","author":"Hata","year":"1998"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-065x.2000.017504.x","type":"journal-article"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01454","type":"journal-article"},{"key":"ref48","first-page":"9","type":"journal-article","volume-title":"Novel asthma treatments: advancing beyond approved novel step-up therapies for asthma","author":"Seluk","year":"2025"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.05.030","type":"journal-article"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm-conference.2024.209.1_meetingabstracts.a7002","type":"journal-article"},{"key":"ref51","first-page":"384","type":"journal-article","volume-title":"Eosinophilic asthma: pathophysiology and therapeutic horizons","author":"Hussain","year":"2024"},{"key":"ref52","first-page":"42","type":"journal-article","volume-title":"The emerging roles of eosinophils: implications for the targeted treatment of eosinophilic-associated inflammatory conditions","author":"Lombardi","year":"2022"},{"key":"ref53","first-page":"62","type":"journal-article","volume-title":"The targeted eosinophil-lowering effects of dexpramipexole in clinical studies","author":"Dworetzky","year":"2017"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.05.014","type":"journal-article"},{"key":"ref55","first-page":"33","type":"journal-article","volume-title":"Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy","author":"Cruz","year":"2019"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2019.01.004","type":"journal-article"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-063011-092449","type":"journal-article"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2016.04.003","type":"journal-article"},{"key":"ref59","first-page":"67","type":"journal-article","volume-title":"Inhaling medicines: delivering drugs to the body through the lungs","author":"Patton","year":"2007"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1852","type":"journal-article"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.06.024","type":"journal-article"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.07.010","type":"journal-article"},{"key":"ref63","first-page":"118","type":"journal-article","volume-title":"Gaining the upper hand on pulmonary drug delivery","author":"Tyrrell","year":"2014"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00075614","type":"journal-article"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2004.09.005","type":"journal-article"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20178","type":"journal-article"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39553.670231.25","type":"journal-article"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.09.028","type":"journal-article"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2406673","type":"journal-article"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(17)30125-x","type":"journal-article"},{"key":"ref71","first-page":"782","type":"journal-article","volume-title":"Verekitug, a novel antibody antagonist to the TSLP receptor in adults with asthma: a 32-week randomized phase 1b multiple ascending-dose trial","author":"Singh","year":"2026"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.01.017","type":"journal-article"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.2147\/itt.s532291","type":"journal-article"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00837-2022","type":"journal-article"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.06.002","type":"journal-article"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01273-4","type":"journal-article"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01461-2024","type":"journal-article"}],"container-title":["Tuberculosis and Respiratory Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-trd.org\/upload\/pdf\/trd-2026-0033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-trd.org\/journal\/view.php?doi=10.4046\/trd.2026.0033","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-trd.org\/upload\/pdf\/trd-2026-0033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:18:13Z","timestamp":1782980293000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-trd.org\/journal\/view.php?doi=10.4046\/trd.2026.0033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"URL":"https:\/\/doi.org\/10.4046\/trd.2026.0033","relation":{},"ISSN":["1738-3536","2005-6184"],"issn-type":[{"value":"1738-3536","type":"print"},{"value":"2005-6184","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"2026-02-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-21","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-01","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}